News about Global Pharma

Insilico Medicine and Eli Lilly Expand Collaboration to Accelerate AI-Driven Drug Discovery

The partnership aims to combine Insilico’s advanced Pharma.AI platforms with Lilly’s deep expertise in disease biology and drug development to jointly discover and advance innovative therapies for unmet medical needs.

Global Pharma | 11/11/2025 | By Dineshwori |  193

ABPI Calls for Urgent Steps to Boost UK Life Sciences Investment in Pre-Budget Submission

The Association of the British Pharmaceutical Industry (ABPI) has called on the government to take urgent action to reverse a decade-long decline in investment and restore the UK’s position as a global leader in life sciences.

Global Pharma | 10/11/2025 | By Dineshwori |  149

Eli Lilly and SanegeneBio Partner to Develop RNAi Therapies for Metabolic Diseases

SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, has entered into a global research and licensing collaboration with Eli Lilly and Company to advance RNAi candidates for metabolic diseases.

Global Pharma | 10/11/2025 | By Dineshwori |  168

FireGate Biotech Emerges as a New Force in Translational Immunology

Rather than chasing single indications, FireGate’s framework is designed as an adaptable immune network, a modular system capable of responding to multiple disease environments and evolving alongside the immune landscape itself.

Global Pharma | 07/11/2025 | By Dineshwori

Eli Lilly Appoints New Executives, Expands Senior Leadership Roles to Drive Next Phase of Growth

Eli Lilly has appointed Carole Ho and Adrienne Brown to lead the company’s expansion in neuroscience and immunology, while also broadening the responsibilities of Daniel Skovronsky and Jacob Van Naarden to further strengthen its leadership team.

Global Pharma | 07/11/2025 | By Dineshwori |  294

Acumed Expands CMF Capabilities with Acquisition of TECHFIT Digital Surgery Assets

Through the deal, Acumed gains full ownership of TECHFIT Digital Surgery's proprietary technologies, including its digital surgical planning and reconstruction platform.

Global Pharma | 06/11/2025 | By Dineshwori |  145

Dynavax, Vaxart Enter Exclusive Global License Agreement for Novel Oral COVID-19 Vaccine

Under the terms of the agreement, Dynavax will receive exclusive, worldwide rights to develop and commercialise oral COVID-19 vaccines based on Vaxart’s delivery platform.

Global Pharma | 06/11/2025 | By Dineshwori |  235

WHO and Bayer Renew Partnership to Combat NTDs

The World Health Organization (WHO) and Bayer AG have renewed their partnership to combat Chagas disease, sleeping sickness, and taeniasis, with Bayer pledging USD 9.45 million to support WHO’s efforts through 2030.

Global Pharma | 06/11/2025 | By Dineshwori |  134

Novo Nordisk Submits Updated Proposal to Acquire Metsera in Multi-Billion-Dollar Deal

Novo Nordisk has confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera, which has been declared superior by Metsera’s board of directors.

Global Pharma | 06/11/2025 | By Dineshwori

FDA Grants ODD to Leukogene Therapeutics' M2T-CD33 (LTI-214) for Treating Acute Myeloid Leukemia

The US FDA has granted ODD to Leukogene Therapeutics’ M2T-CD33 (LTI-214) for the treatment of Acute Myeloid Leukemia (AML). The designation highlights the pressing need for new treatment options and acknowledges LTI-214’s potential as a novel and targeted therapy for this aggressive form of blood cancer.

Global Pharma | 05/11/2025 | By Dineshwori |  107